Your selections:
- Lamb, David S., Denham, James W., D'Este, Catherine, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, Delahunt, Brett
- Galvão, Daniel A., Spry, Nigel, Denham, James, Taaffe, Dennis R., Cormie, Prue, Joseph, David, Lamb, David S., Chambers, Suzanne K., Newton, Robert U.
- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Kenny, Lizbeth, Duchesne, Gillian, Delahunt, Brett, McElduff, Patrick, Joseph, David, Spry, Nigel A., Lamb, David S., Tai, Keen-Hun, Matthews, John, Atkinson, Chris, Turner, Sandra, Christie, David
- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.
- D'Amico, Anthony V., Chen, Ming-Hui, de Castro, Mario, Loffredo, Marian, Lamb, David S., Steigler, Allison, Kantoff, Philip W., Denham, James W.
A methodology for the analysis of PSA response signatures
- Ebert, Martin A., Lamb, David S., Joseph, David J., Steigler, Allison, Denham, James W.
- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David
PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?
- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine
- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth
- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David
- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine
- Buffart, Laurien M., Newton, Robert U., Chinapaw, Mai J., Taaffe, Dennis R., Spry, Nigel A., Denham, James W., Joseph, David J., Lamb, David S., Brug, Johannes, Galvão, Daniel A.
Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer
- Denham, James W., Wilcox, Chantelle, Gogna, Nirdosh Kumar, Ebert, Martin, Delahunt, Brett, McElduff, Patrick, Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizabeth, Tai, Keen-Hun
Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?
- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.
Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter)
- Lamb, David S., Delahunt, Brett, Denham, James, Slaney, David
Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial
- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison
Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial
- Steigler, Allison, Denham, James W., Tai, Keen-Hun, Wynne, Chris, Lamb, David S., Spry, Nigel A., Joseph, David, Matthews, John, Atkinson, Chris, Turner, Sandra, North, John, Christie, David
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer
- Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial
- Galvão, Daniel A., Spry, Nigel, Taaffe, Dennis R., Denham, James, Joseph, David, Lamb, David S., Levin, Greg, Duchesne, Gillian, Newton, Robert U.
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial
- Sridharan, Swetha, Steigler, Allison, Attia, John, Holliday, Elizabeth G., Denham, James W., Spry, Nigel A., Joseph, David, Lamb, David S., Matthews, John H., Atkinson, Chris, Tai, Keen-Hun, Duchesne, Gillian, Christie, David
Are you sure you would like to clear your session, including search history and login status?